Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines

Ting Yao Wang, Wei Ming Chen, Lan Yan Yang, Chao Yu Chen, Wen Chi Chou, Yi Yang Chen, Chih Cheng Chen, Kuan Der Lee, Chang Hsien Lu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Induction chemotherapy with docetaxel improved outcome in advanced head and neck squamous cell carcinoma (HNSCC) patients, but docetaxel was not recommended in liver dysfunction patients for treatment toxicities. Severe neutropenic events (SNE) including severe neutropenia (SN) and febrile neutropenia (FN) still developed in these patients with normal serum transaminases. Ultrasonography (US) fibrotic score represented degree of hepatic parenchymal damage and showed good correlation to fibrotic changes histologically. This study aims to evaluate the association of US fibrotic score with docetaxel treatment-related SNE in advanced HNSCC patients with normal serum transaminases. Between 1 January 2011 and 31 December 2013, a total of 47 advanced HNSCC patients treated with induction docetaxel were enrolled. The clinical features were collected to assess predictive factors for SNE. The patients were divided into two groups by the US fibrotic score with a cutoff value of 7. The Mann–Whitney U test and logistic regression method were used for the risk factor analysis. The background, treatment, and response were similar in both groups except for lower lymphocyte and platelet count in patients with higher US score. Twenty-seven patients (51 %) developed grade 3/4 neutropenia, and more SNE developed in patients with US score ≧7. In multivariate analysis, only US score ≥7 was independent predictive factor for developing SN (hazard ratio 7.71, p = 0.043) and FN (hazard ratio 20.95, p = 0.008). US score ≥7 is an independent risk factor for SNE in advanced HNSCC patients treated with induction docetaxel. US score could be used for risk prediction of docetaxel-related SNE.

Original languageEnglish
Pages (from-to)4697-4703
Number of pages7
JournalSupportive Care in Cancer
Volume24
Issue number11
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

docetaxel
Tranylcypromine
Induction Chemotherapy
Head and Neck Neoplasms
Neutropenia
Ultrasonography
Fever
Liver
Serum
Therapeutics
Febrile Neutropenia
Transaminases
Lymphocyte Count

Keywords

  • Docetaxel
  • Neutropenia
  • Risk factors
  • Ultrasonography

ASJC Scopus subject areas

  • Oncology

Cite this

Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines. / Wang, Ting Yao; Chen, Wei Ming; Yang, Lan Yan; Chen, Chao Yu; Chou, Wen Chi; Chen, Yi Yang; Chen, Chih Cheng; Lee, Kuan Der; Lu, Chang Hsien.

In: Supportive Care in Cancer, Vol. 24, No. 11, 01.11.2016, p. 4697-4703.

Research output: Contribution to journalArticle

Wang, Ting Yao ; Chen, Wei Ming ; Yang, Lan Yan ; Chen, Chao Yu ; Chou, Wen Chi ; Chen, Yi Yang ; Chen, Chih Cheng ; Lee, Kuan Der ; Lu, Chang Hsien. / Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines. In: Supportive Care in Cancer. 2016 ; Vol. 24, No. 11. pp. 4697-4703.
@article{589355ed20324108922b4c49d0213d75,
title = "Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines",
abstract = "Induction chemotherapy with docetaxel improved outcome in advanced head and neck squamous cell carcinoma (HNSCC) patients, but docetaxel was not recommended in liver dysfunction patients for treatment toxicities. Severe neutropenic events (SNE) including severe neutropenia (SN) and febrile neutropenia (FN) still developed in these patients with normal serum transaminases. Ultrasonography (US) fibrotic score represented degree of hepatic parenchymal damage and showed good correlation to fibrotic changes histologically. This study aims to evaluate the association of US fibrotic score with docetaxel treatment-related SNE in advanced HNSCC patients with normal serum transaminases. Between 1 January 2011 and 31 December 2013, a total of 47 advanced HNSCC patients treated with induction docetaxel were enrolled. The clinical features were collected to assess predictive factors for SNE. The patients were divided into two groups by the US fibrotic score with a cutoff value of 7. The Mann–Whitney U test and logistic regression method were used for the risk factor analysis. The background, treatment, and response were similar in both groups except for lower lymphocyte and platelet count in patients with higher US score. Twenty-seven patients (51 {\%}) developed grade 3/4 neutropenia, and more SNE developed in patients with US score ≧7. In multivariate analysis, only US score ≥7 was independent predictive factor for developing SN (hazard ratio 7.71, p = 0.043) and FN (hazard ratio 20.95, p = 0.008). US score ≥7 is an independent risk factor for SNE in advanced HNSCC patients treated with induction docetaxel. US score could be used for risk prediction of docetaxel-related SNE.",
keywords = "Docetaxel, Neutropenia, Risk factors, Ultrasonography",
author = "Wang, {Ting Yao} and Chen, {Wei Ming} and Yang, {Lan Yan} and Chen, {Chao Yu} and Chou, {Wen Chi} and Chen, {Yi Yang} and Chen, {Chih Cheng} and Lee, {Kuan Der} and Lu, {Chang Hsien}",
year = "2016",
month = "11",
day = "1",
doi = "10.1007/s00520-016-3318-8",
language = "English",
volume = "24",
pages = "4697--4703",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines

AU - Wang, Ting Yao

AU - Chen, Wei Ming

AU - Yang, Lan Yan

AU - Chen, Chao Yu

AU - Chou, Wen Chi

AU - Chen, Yi Yang

AU - Chen, Chih Cheng

AU - Lee, Kuan Der

AU - Lu, Chang Hsien

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Induction chemotherapy with docetaxel improved outcome in advanced head and neck squamous cell carcinoma (HNSCC) patients, but docetaxel was not recommended in liver dysfunction patients for treatment toxicities. Severe neutropenic events (SNE) including severe neutropenia (SN) and febrile neutropenia (FN) still developed in these patients with normal serum transaminases. Ultrasonography (US) fibrotic score represented degree of hepatic parenchymal damage and showed good correlation to fibrotic changes histologically. This study aims to evaluate the association of US fibrotic score with docetaxel treatment-related SNE in advanced HNSCC patients with normal serum transaminases. Between 1 January 2011 and 31 December 2013, a total of 47 advanced HNSCC patients treated with induction docetaxel were enrolled. The clinical features were collected to assess predictive factors for SNE. The patients were divided into two groups by the US fibrotic score with a cutoff value of 7. The Mann–Whitney U test and logistic regression method were used for the risk factor analysis. The background, treatment, and response were similar in both groups except for lower lymphocyte and platelet count in patients with higher US score. Twenty-seven patients (51 %) developed grade 3/4 neutropenia, and more SNE developed in patients with US score ≧7. In multivariate analysis, only US score ≥7 was independent predictive factor for developing SN (hazard ratio 7.71, p = 0.043) and FN (hazard ratio 20.95, p = 0.008). US score ≥7 is an independent risk factor for SNE in advanced HNSCC patients treated with induction docetaxel. US score could be used for risk prediction of docetaxel-related SNE.

AB - Induction chemotherapy with docetaxel improved outcome in advanced head and neck squamous cell carcinoma (HNSCC) patients, but docetaxel was not recommended in liver dysfunction patients for treatment toxicities. Severe neutropenic events (SNE) including severe neutropenia (SN) and febrile neutropenia (FN) still developed in these patients with normal serum transaminases. Ultrasonography (US) fibrotic score represented degree of hepatic parenchymal damage and showed good correlation to fibrotic changes histologically. This study aims to evaluate the association of US fibrotic score with docetaxel treatment-related SNE in advanced HNSCC patients with normal serum transaminases. Between 1 January 2011 and 31 December 2013, a total of 47 advanced HNSCC patients treated with induction docetaxel were enrolled. The clinical features were collected to assess predictive factors for SNE. The patients were divided into two groups by the US fibrotic score with a cutoff value of 7. The Mann–Whitney U test and logistic regression method were used for the risk factor analysis. The background, treatment, and response were similar in both groups except for lower lymphocyte and platelet count in patients with higher US score. Twenty-seven patients (51 %) developed grade 3/4 neutropenia, and more SNE developed in patients with US score ≧7. In multivariate analysis, only US score ≥7 was independent predictive factor for developing SN (hazard ratio 7.71, p = 0.043) and FN (hazard ratio 20.95, p = 0.008). US score ≥7 is an independent risk factor for SNE in advanced HNSCC patients treated with induction docetaxel. US score could be used for risk prediction of docetaxel-related SNE.

KW - Docetaxel

KW - Neutropenia

KW - Risk factors

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=84975290477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975290477&partnerID=8YFLogxK

U2 - 10.1007/s00520-016-3318-8

DO - 10.1007/s00520-016-3318-8

M3 - Article

VL - 24

SP - 4697

EP - 4703

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 11

ER -